Brokerages expect Vericel Corp (NASDAQ:VCEL) to post earnings per share of ($0.19) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Vericel Corp’s earnings. Vericel Corp reported earnings of ($0.08) per share during the same quarter last year, which suggests a negative year over year growth rate of 137.5%. The firm is expected to announce its next earnings results on Tuesday, May 9th.
According to Zacks, analysts expect that Vericel Corp will report full-year earnings of ($0.57) per share for the current year, with EPS estimates ranging from ($0.73) to ($0.42). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.60) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that cover Vericel Corp.
Several brokerages recently commented on VCEL. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price (down previously from $9.00) on shares of Vericel Corp in a report on Monday, March 13th. Piper Jaffray Companies began coverage on shares of Vericel Corp in a report on Thursday, December 22nd. They set an “overweight” rating and a $6.00 price objective on the stock.
Shares of Vericel Corp (NASDAQ:VCEL) remained flat at $2.60 during mid-day trading on Monday. The company had a trading volume of 159,833 shares. Vericel Corp has a one year low of $1.96 and a one year high of $4.55. The firm’s market cap is $85.08 million. The stock has a 50 day moving average price of $2.77 and a 200-day moving average price of $2.69.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its position in Vericel Corp by 0.5% in the fourth quarter. Renaissance Technologies LLC now owns 436,900 shares of the biotechnology company’s stock valued at $1,311,000 after buying an additional 2,200 shares during the last quarter. DSC Advisors L.P. bought a new position in Vericel Corp during the fourth quarter valued at about $1,091,000. Alyeska Investment Group L.P. bought a new position in Vericel Corp during the fourth quarter valued at about $2,063,000. Finally, Stonepine Capital Management LLC increased its position in Vericel Corp by 84.1% in the fourth quarter. Stonepine Capital Management LLC now owns 1,883,800 shares of the biotechnology company’s stock valued at $5,651,000 after buying an additional 860,752 shares during the last quarter. Institutional investors own 24.31% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/05/20/brokerages-expect-vericel-corp-vcel-will-post-earnings-of-0-19-per-share-updated-updated-updated.html.
Vericel Corp Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corp and related companies with MarketBeat.com's FREE daily email newsletter.